Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

Jizu Zhi,Sean Khozin,Deborah Kuk,Aracelis Z. Torres,Rachael Sorg,Shannon E. Lee,Rebecca A. Miksad,Richard Pazdur,Amy P. Abernethy

Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

2018

Jizu Zhi
Sean Khozin
Deborah Kuk
Aracelis Z. Torres
Rachael Sorg
Shannon E. Lee
Rebecca A. Miksad
Richard Pazdur
Amy P. Abernethy

6553Background: Poor performance status (PS) is associated with worse clinical outcomes for pts with mNSCLC. However, in the real-world PS is not routinely captured in electronic health records (EH...

Keywords:

Nivolumab
Cancer research
Physical therapy
Body mass index
Lung cancer
Pembrolizumab
Medicine
health records
Oncology
overall survival
in patient
Internal medicine
non small cell
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations